From bloodjournal.hematologylibrary.org at MARQUETTE UNIV on October 2, 2011. For personal use only.

1999 93: 55-65

Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
B. Barlogie, S. Jagannath, K.R. Desikan, S. Mattox, D. Vesole, D. Siegel, G. Tricot, N. Munshi, A. Fassas, S. Singhal, J. Mehta, E. Anaissie, D. Dhodapkar, S. Naucke, J. Cromer, J. Sawyer, J. Epstein, D. Spoon, D. Ayers, B. Cheson and J. Crowley

Updated information and services can be found at: http://bloodjournal.hematologylibrary.org/content/93/1/55.full.html Articles on similar topics can be found in the following Blood collections Clinical Trials and Observations (3288 articles) Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.

From bloodjournal.hematologylibrary.org at MARQUETTE UNIV on October 2, 2011. For personal use only.

Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
By B. Barlogie, S. Jagannath, K.R. Desikan, S. Mattox, D. Vesole, D. Siegel, G. Tricot, N. Munshi, A. Fassas, S. Singhal, J. Mehta, E. Anaissie, D. Dhodapkar, S. Naucke, J. Cromer, J. Sawyer, J. Epstein, D. Spoon, D. Ayers, B. Cheson, and J. Crowley
Between August 1990 and August 1995, 231 patients (median age 51, 53% Durie-Salmon stage III, median serum -2-microglobulin 3.1 g/L, median C-reactive protein 4 g/L) with symptomatic multiple myeloma were enrolled in a program that used a series of induction regimens and two cycles of high-dose therapy (Total Therapy). Remission induction utilized noncross-resistant regimens (vincristinedoxorubicin-dexamethasone [VAD], high-dose cyclophosphamide and granulocyte-macrophage colony-stimulating factor with peripheral blood stem cell collection, and etoposidedexamethasone-cytarabine-cisplatin). The first high-dose treatment comprised melphalan 200 mg/m2 and was repeated if complete (CR) or partial (PR) remission was maintained after the first transplant; in case of less than PR, total body irradiation or cyclophosphamide was added. Interferon-2b maintenance was used after the second autotransplant. Fourteen patients with HLA-compatible donors underwent an allograft as their second high-dose therapy cycle. Eightyeight percent completed induction therapy whereas first and second transplants were performed in 84% and 71% (the majority within 8 and 15 months, respectively). Eight patients (3%) died of toxicity during induction, and 2 (1%) and 6 (4%) during the two transplants. True CR and at least a PR (PR plus CR) were obtained in 5% (34%) after VAD, 15% (65%) at the end of induction, and 26% (75%) after the first and 41% (83%) after the second transplants (intent-to-treat). Median overall (OS) and event-free (EFS) survival durations were 68 and 43 months, respectively. Actuarial 5-year OS and EFS rates were 58% and 42%, respectively. The median time to disease progression or relapse was 52 months. Among the 94 patients achieving CR, the median CR duration was 50 months. On multivariate analysis, superior EFS and OS were observed in the absence of unfavorable karyotypes (11q breakpoint abnormalities, -13 or 13-q) and with low -2microglobulin at diagnosis. CR duration was significantly longer with early onset of CR and favorable karyotypes. Time-dependent covariate analysis suggested that timely application of a second transplant extended both EFS and OS significantly, independent of cytogenetics and -2microglobulin. Total Therapy represents a comprehensive treatment approach for newly diagnosed myeloma patients, using multi-regimen induction and tandem transplantation followed by interferon maintenance. As a result, the proportion of patients attaining CR increased progressively with continuing therapy. This observation is particularly important because CR is a sine qua non for long-term disease control and, eventually, cure. 1999 by The American Society of Hematology.

URE HAS REMAINED an elusive goal of myeloma therapy. With standard melphalan-prednisone (MP) or combination chemotherapy using additional cytotoxic drugs, stringently dened complete remission (CR) rates have not exceeded 5% and median survival has not been extended beyond 3 years.1,2 When high-dose therapy with melphalan (MEL) was introduced in the mid 1980s, CRs were observed more frequently, and attainment of CR became a primary trial objective as a potential prelude to long-term disease control.3-7 Extensive phase II studies, initially with autologous bone marrow transplants (ABMT) and, more recently, with mobilized peripheral blood stem cell (PBSC) support (decreasing the duration of marrow aplasia and treatment-related mortality [TRM]), indicated that drug resistance could be overcome by dose escalation. Thus, in newly diagnosed disease, up to 50% of patients achieved stringently dened CR.8-13 With PBSC, the duration of bone marrow aplasia was shortened to a few days so that TRM could be reduced to well under 5%.14 A randomized trial by the Intergroupe Francais du Myelome (IFM) showed better outcome with high-dose therapy than with standard chemotherapy among 200 patients with newly diagnosed disease.15 In 1989, the Total Therapy program was designed using all treatment tools available at the time to maximize the chance of CR induction in newly diagnosed myeloma patients.16 After induction chemotherapy with noncross-resistant regimens of vincristine, doxorubicin, dexamethasone (VAD); high-dose cyclophosphamide (HDCTX); and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) patients underwent two cycles of MEL-based high-dose therapy with PBSC support and subsequent interferon (IFN) maintenance. With a median follow-up of 4.2 years among surviving patients, we now report the nal
Blood, Vol 93, No 1 (January 1), 1999: pp 55-65

results of this trial. A comparative analysis of a subset of 123 untreated patients receiving Total Therapy with patients receiving standard therapy according to Southwest Oncology Group protocols has been reported previously.17
MATERIALS AND METHODS Total Therapy. The treatment plan is outlined in Table 1. The VAD regimen was applied in standard fashion for two to three cycles because of its marked and speedy tumor cell kill without inicting hematopoietic stem cell compromise.18 After intravenous hydration for 12 hours, HDCTX was administered at doses of 1.5 g/m2 every 4 hours 4 for a total of 6 g/m2 along with mesna 6 g/m2 followed by subcutaneous administration of granulocyte-macrophage colony-stimulating factor (GM-CSF) 250 g/m2 beginning on day 2 (modied from Gianni et From the Myeloma and Transplantation Research Center (MTRC), University of Arkansas for Medical Sciences, Arkansas Cancer Research Center, Little Rock, AR; St Vincents Comprehensive Cancer Center, New York, NY; the Medical College of Wisconsin, Milwaukee, WI; the Greenbaum Cancer Center, Baltimore, MD; CTEP, National Cancer Institute, Bethesda, MD; and the Fred Hutchinson Cancer Research Center and Southwest Oncology Group Offce, Seattle, WA. Submitted May 11, 1998; accepted September 1, 1998. Supported in part by Grant No. CA55819 from the National Cancer Institute. Address reprint requests to B. Barlogie, MD, PhD, Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, 4301 W Markham Slot 776, Little Rock, AR 72205. The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. section 1734 solely to indicate this fact. 1999 by The American Society of Hematology. 0006-4971/99/9301-0031$3.00/0
55

From bloodjournal.hematologylibrary.org at MARQUETTE UNIV on October 2, 2011. For personal use only.

56

BARLOGIE ET AL

Table 1. Total Therapy Regimen Induction VAD Vincristine 0.5 mg Daily for 4 days by continuous infusion Adriamycin 10 mg/m2 Dexamethasone 40 mg orally days 1-4, 9-12, 17-20

2---- 2----

Repeat on day 35 3 cycles; in case of 50% tumor regression or insufficient symptomatic relief, move to HDCTX after 2 cycles

HDCTX

Cyclophosphamide 6 g/m2 in 5 divided doses of 1.2 g/m2 every 3 hours Mesna 3.6 g/m2 24 hour CI 1 day GM-CSF 250 g/m2/d PBSC collection Etoposide 100 mg/m2/d Dexamethasone 40 mg days 1-5 Daily for 4 days by continuous infusion Ara-C 1 g/m2 day 5 Cisplatinum 25 mg/m2/d GM-CSF 250 g/m2/d from day 6 until hematologic recovery

EDAP

2---2----

Transplants Tx-1 MEL 100 mg/m2 on days 3, 2; PBSC ABMT on day 0; GM-CSF 250 g/m2/d from day 3-6 Months Tx-2 PR: Repeat MEL 200 mg/m2 PR: MEL 140 mg/m2 on day 4; TBI 850-1,020 cGy in 5-6 fractions on days 3, 2, 1; PBSC ABMT on day 0; GM-CSF 250 g/m2/d from day 1 until hematologic recovery Maintenance IFN sc, Mon-Wed-Fri until relapse Interferon- -2b 3 Start on hematologic recovery after second transplant (granulocytes 1,500/L and platelets 150,000/L) MU/m2

1 until hematologic recovery

Abbreviations: sc, subcutaneous; Mon, Monday; Wed, Wednesday; Fri, Friday.

al19). On hematopoietic recovery with platelets reaching at least 50,000/L, PBSC collection was performed as described previously.20 Daily aphereses of approximately 15 L of blood were continued until at least 5 106 CD34 cells/kg were collected (a quantity judged necessary for the safe conduct of two autotransplants). As a safety precaution, the rst 69 patients also had autologous bone marrow collected under general anesthesia provided that bone marrow plasmacytosis did not exceed 30%. On completion of PBSC collection, the EDAP chemotherapy was administered on an outpatient basis,21 consisting of etoposide 100 mg/m2 daily 4 by continuous infusion, dexamethasone 40 mg orally daily 4, cytarabine 1 g/m2 intravenously over 2 hours on day 5, and cisplatin 25 mg/m2 daily 4 by continuous infusion, followed by GM-CSF 250 g/m2 beginning on day 6 and administered subcutaneously on a daily basis until granulocytes exceeded 2,000/L for 3 days. The rationale for inclusion of EDAP was to target immature tumor cells believed to be present in most patients with myeloma.22 In the absence of tumor progression ( 25% increase in tumor mass), patients proceeded through the entire induction phase and were then offered a rst high-dose therapy cycle with MEL 200 mg/m2 (in two doses of 100 mg/m2 on days 3 and 2) followed by administration of autologous stem cells on day 0. Standard supportive care included antibacterial, antifungal, and antiviral prophylaxis and blood cell component support as needed. In case of sustained partial remission (PR, see below) or CR, a second autotransplant with MEL 200 mg/m2 was performed. The remaining patients received either MEL 140 mg/m2 plus total body irradiation (TBI) 850-1125 cGy or other regimens, usually MEL 200 mg/m2 plus HDCTX 120 mg/kg in case prior radiotherapy prevented the application of TBI. Eleven patients under the age of 50 years with HLA-compatible siblings were allografted after a rst autotransplant. The conditioning regimen consisted of MEL 140 mg/m2 plus TBI 1125 cGy. Three additional patients received a T-cell depleted matched unrelated donor (MUD) bone marrow transplant after

conditioning with thiotepa 10 mg/kg, HDCTX 120 mg/kg, and TBI 1375 cGy in 11 fractions of 125 cGy each. The intent was to complete the second transplant within 3 to 6 months of the rst. After completion of two autotransplants, IFN maintenance was commenced at 3 million U/m2 subcutaneously thrice weekly when granulocytes exceeded 1,500/L and platelets exceeded 100,000/L and continued until disease relapse. The protocol had a provision for potential insurance denial, in which case, at the end of induction with EDAP, MEL 70 mg/m2 with subsequent subcutaneous GM-CSF 250 g/m2 was administered, followed by cyclical administration of VAD and intermediate-dose cyclophosphamide (1 g/m2) along with IFN for 2 years, followed by IFN maintenance indenitely as with autotransplant recipients. There were only seven patients in whom this nontransplant strategy was applied. All patients signed an informed consent in keeping with guidelines of the National Cancer Institute, which had reviewed the Total Therapy program, and of the Institutional Review Board of the University of Arkansas for Medical Sciences and the Arkansas Cancer Research Center. Patient entry began in August 1990 and continued through August 1995. More than 95% of consecutive eligible patients (see below) were enrolled during this time interval; only a few patients declined study participation. Eligibility criteria. Eligible patients had to have symptomatic multiple myeloma using standard diagnostic criteria.23 They had to be previously untreated or had to have received only one cycle of standard chemotherapy. Prior local radiation was permitted. A modied DurieSalmon staging system was applied whereby bone lesions were enumerated not according to the actual number of lesions but according to the number of sites of involvement, using skull, cervical, thoracic, and lumbar spine as well as pelvis and long bones as distinct sites. An upper age limit of 70 years was imposed, although protocol exception was obtained for one patient who was enrolled at the age of 71 years because his physiological status was deemed adequate to withstand the

From bloodjournal.hematologylibrary.org at MARQUETTE UNIV on October 2, 2011. For personal use only.

TOTAL THERAPY FOR NEWLY DIAGNOSED MM

57

potential toxicity from the Total Therapy program. Adequate cardiopulmonary function had to be present at the time of entry on study including a systolic cardiac ejection fraction 50%. Patients could have renal function impairment (creatinine 2 mg/dL, 9%) at protocol entry or poor performance status related to multiple myeloma (Zubrod 2, 8% at diagnosis). However, renal function had to improve after VAD so that serum creatinine could not exceed 2 mg/dL at the time of initiation of HDCTX as well as before rst and second transplant. In addition to standard laboratory parameters, cytogenetic24 and morphological bone marrow examinations were performed.25 Patient follow-up was performed according to protocol guidelines, usually on a monthly basis, to record treatment-related toxicity and antitumor effect. Response, event-free survival (EFS), and overall survival (OS). CR required the disappearance of monoclonal gammopathy in serum and urine on immunoxation analysis and attainment of normal bone marrow aspirate and biopsy with 1% light chain-restricted plasma cells on ow cytometry, on at least two successive occasions at least 2 months apart. PR implied 75% tumor mass reduction including a normal marrow aspirate and biopsy and, in case of Bence Jones proteinuria, reduction to 100 mg/day. For computation of PR and CR rates, all patients were eligible; those dying early before antitumor effect could be established were considered treatment failures. TRM included any death within 60 days for autotransplants and within 100 days for allotransplants. EFS and OS were dated from the time of initiation of the rst cycle of VAD, whereas CR duration was computed from the onset of CR. Events included disease progression/relapse or death from any cause. Relapse was dened as recurrence of monoclonal protein on immunoxation or bone marrow plasmacytosis in case of CR and a 25% increase from minimal tumor mass in case of PR. Disease progression for nonresponsive patients implied at least a 25% increase in tumor mass. Unless otherwise specied, all analyses were performed on an intent-to-treat basis. Statistical analysis. Data were analyzed as of September 1997. EFS and OS distributions were estimated by the product-limit method.26 EFS and OS among categorical prognostic variables measured before start of therapy were compared using the log-rank test.27 EFS and OS comparisons among categorical variables measured after start of therapy were made using landmark analysis.28 Cox regression was used to examine continuous and categorical univariate and multivariate effects of prognostic features on EFS and OS.29 Variables measured after start of therapy were incorporated in the Cox models as time-dependent covariates. Cumulative incidence distributions were calculated for the competing risks of disease-related progression/death (time to progression) and TRM.30 The chi-square test or Fishers exact test (where appropriate) were used to compare cross tabulations of categorical variables. RESULTS

Table 2. Patient and Disease Features

Parameter Median Range %

Age (yrs) Hemoglobin (g/dL) Albumin (g/dL) 2M (mg/L) CRP (mg/L) Creatinine (g/dL) Calcium (g/dL) Cytogenetics (11q; 13, del 13q) Stage III Male White Ig G A Only Bence Jones proteinuria D/nonsecretory light chain One cycle prior chemotherapy Prior local radiation

51 11.0 3.9 3.1 4.0 1.0 9.6

26-71 7.6-16.3 2.0-5.3 0.1-28.5 2.4-263 0.6-10.3 8.2-18.9

( 50) 51 ( 10.0) 34 ( 3.5) 32 ( 4.0) 30 ( 4.0) 47 ( 2.0) 9 ( 11.0) 12

21 53 62 89 61 18 16 5 65 33 18

100

Patient and disease characteristics. Table 2 depicts the pertinent demographic features, which are representative of our referral population of newly diagnosed patients. As indicated, tumor staging was modied so that bone lesions were enumerated according to the number of regional bone sites rather than the number of individual lesions (see Eligibility criteria). Considering hemoglobin ( 8.5 g/dL), calcium ( 12 mg/dL), albumin ( 3.0 g/dL), -2-microglobulin ( 2M; 6 mg/L) and C-reactive protein (CRP; 6 mg/L), 30% had at least one, 14% had two, 4% had three, and 2% had four high-stageassociated features. Sixty-seven percent were untreated, 33% had one cycle of prior chemotherapy, and 18% had prior local radiation. Patient ow through total therapy (Table 3 and Fig 1). All 231 patients completed one cycle of VAD, 224 received two cycles, and 174 received three cycles. By protocol design,

HDCTX could be administered after completion of two cycles of VAD in case 50% tumor mass reduction was not obtained or insufficient subjective improvement, especially in pain, had not been effected. Remission induction deaths included 1 patient with the rst and 4 additional patients with the second and third cycle of VAD (total of 3 suicides related to dexamethasone-induced psychosis), and 1 after HDCTX and 2 after EDAP for a total of 8 (3% of 231 patients). Additional off-study reasons pertained to excessive toxicity in 8, disease progression in 6, or decline in further trial participation in 7 patients; only 7 patients were denied insurance coverage and were entered on the nontransplant arm of the study (see Materials and Methods and Table 3). One hundred ninety-ve patients (84%) completed one transplant and 165 patients (71%) completed two transplants, 84% within 6 months and all within 1 year of the rst transplant. The time interval between rst and second transplant ranged from 2.4 to 11.2 months (median, 4.5 months) (Fig 1). There was no signicant relationship between the interval of the two transplants and the time interval to rst transplant. The second transplant was autologous in 151 and allogeneic in 14 patients, including 3 who received a MUD transplant. Reasons for failure to proceed to second transplant included toxicity with rst transplant in 11 patients (2 deaths),
Table 3. Patient Flow on Total Therapy
Started Treatment Phase of Therapy N % Toxicity (deaths) Off-Study Reasons Platelets 50,000/L Progression Declined

Induction Tx-1 Tx-2 IFN

231 195 165 128

100 84 71 56

16 (8) 11 (2) 12 (6) 34 (0)

0 0 10 0

6 9 2 25

7/7* 10 13 16

*Seven patients without insurance coverage proceeded to nontransplant arm of study (see text).

From bloodjournal.hematologylibrary.org at MARQUETTE UNIV on October 2, 2011. For personal use only.

58

BARLOGIE ET AL

Fig 1. Time course of initiating successive treatment regimens used in Total Therapy, consisting of VAD 2 to 3 (see text), HDCTX GM-CSF with subsequent PBSC collection, EDAP GM-CSF; followed by two cycles of high-dose therapy with hematopoietic stem cell support (Tx-1 and Tx-2); followed by IFN maintenance after completion of two autotransplants (151 patients). Note that G95% of patients completed remission induction by 6 months, first transplant by 8 months, and second transplant by 15 months (for further details, see text). The time interval between first and second transplant regimen ranged from 2.4 to 11.2 months with a median of 4.5 months; 80% completed both transplants within 1 year of study enrollment.

disease progression in 9, and patient preference in 10 patients. One hundred twenty-one patients attaining and sustaining PR underwent a second autotransplant with MEL 200 mg/m2. The conditioning regimen for the remaining patients consisted of MEL 140 mg/m2 and TBI 1125 cGy (n 20) or other regimens (n 10; 8 received MEL 200 mg/m2 HDCTX 120 mg/kg). After two autotransplants, 128 patients (85% of tandem autotransplant recipients) started IFN maintenance, whereas 37 came off-study for reasons listed in Table 3. The time course to initiation of the different phases of study shows that 95% of patients had completed remission induction by 6 months, rst transplant by 8 months, and second transplant by 15 months (Fig 1). Antitumor effect and survival. The incremental increase in both PR and CR rates in relationship to the different phases of study is shown in Fig 2 for all 231 patients on an intent-to-treat basis, whether the designated treatment portion was actually applied or not, and separately for the 165 patients who actually completed two transplants (including allotransplants). Among all patients, the CR rate increased progressively from 5% after VAD to 15% at the end of remission induction to 26% after one transplant and 38% after two transplants, and to 41% with IFN.

The corresponding PR CR rates were 34%, 65%, 75%, 81%, and 83%, respectively. Among the subgroup of 165 patients completing two transplants, the corresponding CR( PR) rates were 6%(37%), 18%(72%), 32%(86%), 48%(95%), and 51%(95%), respectively. The response status was upgraded in 61% (7% to CR) of 28 patients not achieving PR (no response [NR]) after the rst transplant and in 30% of 84 PR patients, so that altogether 38% of 112 patients with PR experienced further tumor cytoreduction. Four patients with PR and 1 with CR had disease progression before second transplant. Among 165 tandem transplant recipients, the nal CR rate was higher if PR status was attained early; thus, the 61 patients achieving PR after VAD had the highest CR rate of 64% after two transplants and IFN compared with only 13% when PR status was not obtained until after the second transplant (Fig 3; P .004). Median durations of OS and EFS have been reached at 68 and 43 months, respectively. The median time to relapse/progression was 52 months. All 7% of TRM events occurred within 24 months (Fig 4). Of the 94 patients achieving CR, the median time to CR was 8.4 months (range, 0.5 to 45 months). The median CR duration was 50 months and was longer in the

Fig 2. Response to Total Therapy in relationship to the individual treatment components, depicting HPR by the stippled columns and CR by the shaded bars. (A) Intent-to-treat analysis including all 231 patients enrolled. PR and CR rates increased steadily with the progression through the different phases of Total Therapy. PR and CR rates are depicted in a cumulative fashion, regardless of whether the individual treatment components were actually administered. (B) PR and CR increments among the 165 patients who actually completed two transplants (128 of 151 tandem autotransplant recipients also started IFN).

From bloodjournal.hematologylibrary.org at MARQUETTE UNIV on October 2, 2011. For personal use only.

TOTAL THERAPY FOR NEWLY DIAGNOSED MM

59

Fig 3. Analysis of CR rate in relationship to time of onset of first PR among the 165 patients completing tandem transplants including 14 who received an allograft. The horizontal axis depicts the serial components of Total Therapy along with the number of patients achieving first PR status as a result of the indicated therapeutic intervention along with the cumulative PR rate. For example, 61 patients already responding to VAD (37%) had the highest CR rate after two transplants (64%) compared with a CR rate of 37% among the 22 patients attaining PR only after the first cycle of MEL 200 mg/m2. Thus, CR rate was highest in VAD-sensitive myeloma.

absence of abnormalities of chromosomes 11 and 13 ( 69 v 26 months, P .05; Fig 5). Table 4 depicts the clinical outcome dated from second transplant in relationship to response status and treatment regimen. Among autograft recipients, those already in CR and receiving MEL 200 mg/m2 had the longest EFS and OS durations. Similar durations of disease control were observed for the 70 patients in PR (but not CR) receiving autotransplantsupported MEL 200 mg/m2 and the 28 patients with less than PR (NR) receiving combination therapy. The 14 allograft recipients (all in PR) had inferior EFS/OS durations compared with the other three groups, but displayed a higher frequency of adverse cytogenetics (50% v 19% with autograft recipients; P .006) (see below). Prognostic factors. On univariate analysis of 15 pretreatment variables, 10 had signicant associations with OS, 7 with EFS, and 6 with both EFS and OS (Table 5 for categorical variables; this was also true for continuous variables where applicable, data not shown). Two parameters retained independent signicance on multivariate analysis among the 218 patients in whom all parameters were available, using continuous variables where appropriate. Thus, superior EFS and OS

were noted in the absence of unfavorable cytogenetics (11q breakpoints and/or partial or complete deletions of chromosome 13 [13q , 13]) (EFS, P .0001; OS, P .0001) and with low levels of 2M (EFS, P .001; OS, P .0007). On further scrutiny, the presence of unfavorable cytogenetics (S 11/13) identied a subgroup of 23 patients among the 68 with 2M 4 mg/L whose median EFS and OS were only 1.7 and 2.1 years, respectively (Fig 6). This group of 10% of all patients fared distinctly worse than the other three cytogenetic/ 2M subgroups. CR duration was signicantly longer with early onset of CR (P .01) and favorable cytogenetics (P .03). To appreciate the potential impact of response and regimen intensity delivered with tandem transplants, a time-dependent covariate analysis was conducted among the 229 patients with both 2M and cytogenetic data available. Multivariate regression analysis considered the additional importance of time to PR, CR, and one or two transplants alone and in combination (Table 6). In addition to cytogenetics and 2M, application of a second transplant (yes or no) and the timeliness of this approach extended both EFS and OS markedly. Whereas signicant on univariate analysis for both EFS (P .02) and OS (P .02),

Fig 4. (A) EFS and OS with Total Therapy from initiation of VAD. Median durations have been reached at 3.6 and 5.7 years, respectively. (B) Time to disease progression or relapse (see text) since initiation of therapy, with toxic or incidental deaths not related to disease progression/relapse being censored. TRM was 7% by 2 years.

From bloodjournal.hematologylibrary.org at MARQUETTE UNIV on October 2, 2011. For personal use only.

60

BARLOGIE ET AL

Fig 5. (A) Time to onset of CR status among 94 patients eventually achieving CR; 90% attained CR status within 18 months. (B) CR duration from first onset of CR was 50 months. The 17 patients (18%) with abnormalities of chromosomes 11 and/or 13 ( 11/13) had a significantly shorter CR duration than the remaining patients (P F .05).

attaining CR in a timely fashion was less signicant once dose intensity parameters had been included. When serial landmark analyses were performed at 11, 12, 13, 14, 15, and 16 months, EFS and OS both were longer among the patients who had received a second transplant within 13 months (when nearly 85% of second transplants had been completed) compared with the others receiving their second cycle of high-dose therapy later or not at all. The proportion of high-risk patients (unfavorable cytogenetics and high 2M) was not different regardless of whether a second transplant had been performed at any of the landmarks examined. Interestingly, the difference in outcome between the group completing a second transplant and the remaining patients gradually emerged by 12 months and was lost by 15 months. This pattern supports the results of the Cox regression model that identied timelines of a second transplant as a signicant variable for clinical outcome. Toxicities. The VAD regimen used, by design, virtually nonmyelosuppressive doses of doxorubicin so that the profound immunosuppressive effects of high-dose dexamethasone would not be associated with signicant neutropenia and hence enhanced risk of serious infections. Median durations of critical neutropenia ( 500/L) and thrombocytopenia ( 50,000/L) typically did not exceed 1 week for the remainder of induction regimens and both transplants. Grade III/IV extramedullary toxicities are summarized in Table 7. No serious toxicity was noted in more than two thirds with VAD, in approximately one

third with HDCTX, in three quarters with EDAP, and in one third with MEL 200 mg/m2 administered with either rst or second transplant, even when HDCTX was added to MEL 200 mg/m2. However, as anticipated, with added TBI more toxicity was encountered so that only 10% had no serious extramedullary toxicity. TRM was 2% with VAD; 1% with HDCTX, EDAP, and rst transplant; 2% with second autotransplant using MEL 200 mg/m2 alone or with added HDCTX and rose to 5% with added TBI. Among the 14 allotransplant recipients, 21% died within 100 days and 50% within 12 months, mainly from transplant-related complications. With the various induction regimens, bacteremia/pneumonia occurred in 10% to 30% of patients; thromboembolic events were observed in about 10% each with VAD and HDCTX. Capillary leak syndrome, mainly related to GM-CSF administration, was noted among 10% of patients during the HDCTX plus GM-CSF portion of the trial. With autologous transplants, the incidence of grade III mucositis was 30% to 40%, serious diarrhea occurred in 10% to 15% of patients, and pneumonia/sepsis was more common with TBI during the second transplant (40%) as opposed to 25% to 30% with MEL 200 mg/m2 HDCTX. Most of the induction regimens were administered in the outpatient setting except for mandatory admission to accommodate hydration (for 2 to 3 days) with the HDCTX phase of therapy. With rst and second autotransplants, the median durations of hospitalization were 13
165)
Median Months

Table 4. Clinical Outcome After Second Transplant (N

Response Before Tx-2

Regimen

%ED

%CR

P*

EFS

OS

CR

CR PR NR PR

MEL200 MEL200 MEL-TBI or MEL-HDCTX MEL-TBI or Thio/TBI/HDCTX

53 70 28 14

2 1 4 21

96 37 7 36

.001 .003 .02

78 52 37 31

80 68 81 30

69 33 22 17

.01

.003

*P values .05 are not reported. Allogeneic transplants, all others are autologous. Abbreviations: ED, early death 60 days; MEL 200, melphalan 200 mg/m2; MEL-TBI, melphalan 140 mg/m2 cGy); HDCTX, high-dose cyclophosphamide 120 mg/kg; Thio, thiotepa 10 mg/kg.

total body irradiation (850-1,125

From bloodjournal.hematologylibrary.org at MARQUETTE UNIV on October 2, 2011. For personal use only.

TOTAL THERAPY FOR NEWLY DIAGNOSED MM Table 5. Prognostic Factors at Diagnosis

Parameter N EFS (mos)

61

OS (mos)

Karyotype No 11/13 11/13 Bartl grade 1 1 2M (mg/L) 4.0 4.0 CRP (mg/L) 4.0 4.0 Hgb (g/dL) 10.0 10.0 Creat (g/dL) 2.0 2.0 Albumin (g/dL) 3.5 3.5 Isotype Non-Ig IgA Age (yrs) 60 60 Calcium (g/dL) 11.0 11.0 LDH (U/L) 190 190 BM PC (%) 50% 50% Stage III III Sex Male Female Race White Non-white Total

182 49 142 60 161 68 120 93 151 80 211 20 158 73 190 41 181 50 204 27 181 49 121 91 108 123 143 88 206 25 231

52 25 53 28 51 26 57 30 53 29 46 28 43 52 50 33 50 32 49 23 49 33 50 34 43 46 41 53 43 49 43

.0002

84 34 81 43 84 50 84 62 84 60 84 44 84 55 84 47 84 50 68 44 82 57 80 62 84 65 68 82 65 78 68

.0001

months). IFN was discontinued because of disease progression or relapse in 25 patients and because of toxicity in 34 patients (mainly persistent malaise). Delayed ( 6 months) PR to CR conversion was observed in 7 patients, including 3 on IFN maintenance (8, 18, and 41 months).
DISCUSSION

.002

.0004

.0002

.003

.0003

.008

.0008

.009

.05

.01

.9

.02

.04

.03

.09

.03

.06

.05

.2

.09

.1

.1

.3

.2

.5

.4

.7

.6

and 14 days, respectively, and over one third of the patients were hospitalized for no more than 1 week. IFN maintenance. IFN maintenance was commenced in 85% of 151 patients completing two autotransplants, with a median time to starting IFN of 2 months ( range, 1 to 14 months). Reasons for not commencing IFN included incomplete platelet recovery ( 100,000/L, 9%), patient refusal (3%), or physician judgment that the anticipated toxicity from IFN would interfere with still ongoing recovery of performance status from a second transplant (2%); 2 patients (1%) died within 76 days after second transplant. The duration of IFN maintenance ranged from 0.5 to 65 months (median, 22

The Total Therapy program represents the rst trial for newly diagnosed patients with multiple myeloma that used multiregimen induction followed by two cycles of high-dose cytotoxic therapy (tandem transplant), regardless of responsiveness to treatment, followed by IFN maintenance. As a result of this approach that incorporated all treatment strategies available at the time of initiation of this trial, we were able to show a progressive increase in stringently dened CR rates during the induction sequence and, especially, as a result of the two high-dose therapy cycles, raising the nal CR to the 40% range using an intent-to-treat analysis. It is difficult to evaluate the contribution of TBI or added cytotoxic drugs to MEL to disease control for those patients with less than PR at the time of second autotransplant. However, among autograft recipients, the incidence of 7% CR with combination therapy among 28 patients with less than PR status before second transplant compared with 37% with MEL 200 mg/m2 for 70 patients in PR (but not yet in CR) suggests that the addition of TBI or other drugs to MEL may not be superior to MEL 200 mg/m2 alone (P .003). This is substantiated by comparable durations of EFS (52 v 37 months, P .2) and OS (68 v 81 months, P .9) after MEL 200 versus combination therapy (Table 4). Superior EFS and OS after MEL 200 mg/m2 compared with other high-dose regimens have also been reported by Powles et al.11 The 7 patients who were denied insurance coverage and received intermediate dose MEL 70 mg/m2 and cyclical chemoimmunotherapy (VAD, cyclophosphamide, IFN) faired well (EFS 43 months, OS 62 months), although only 1 patient had unfavorable cytogenetics, 2M elevation, or hemoglobin levels 10 g/dL. The allogeneic transplant population is too small to comment on a graft-versus-myeloma effect. The observation of higher CR rates after successful completion of two transplants the sooner PR status was attained suggests that sensitivity to high-dose MEL alone or in combination with TBI or other drugs is greater when sensitivity to standard VAD is preserved. Conversely, resistance to glucocorticoids, multidrug resistance (MDR)-associated agents like doxorubicin and etoposide, and other alkylators such as cyclophosphamide and cisplatin may confer a relative degree of resistance to myeloablative therapy as well. The observation of a modest CR rate of 15% at the end of ve induction cycles with three different regimens raises the question whether a similar outcome could have been obtained if remission induction had been limited to a few cycles of dexamethasone pulsing to control patients symptoms and disease-related complications. Randomized trials of minimal remission induction versus maximum tumor cytoreduction before transplant are needed to answer this important issue. Analysis of prognostic factors identied the presence of certain cytogenetic abnormalities as critically important.31 As reported previously, the exact molecular mechanisms resulting from these chromosomal abnormalities and the inferior progno-

From bloodjournal.hematologylibrary.org at MARQUETTE UNIV on October 2, 2011. For personal use only.

62

BARLOGIE ET AL

Fig 6. Significantly shorter EFS (A) and OS (B) in 23 patients (10%) with 2M G 4 and unfavorable karyotypes (S 11/13) compared with the 206 remaining patients (161 with 2M I 4 mg/L and 45 with 2M G 4 mg/L but absence of S 11/13).

sis conferred have yet to be identied. 2M before treatment was conrmed as a dominant prognostic variable.32 To appreciate the independent prognostic contributions of disease sensitivity to treatment (onset of PR and CR) and of dose intensity (one and two transplants), a time-dependent covariate analysis was performed in the context of a multivariate regression approach. In the presence of these four additional variables, timely completion of two transplants emerged as a highly signicant factor for both EFS and OS in addition to cytogenetics and 2M (Table 6). Serial landmark analyses showed that application of two transplants within 13 months from initiation of therapy improved both EFS and OS. The optimal timing seemed to be within 13 months from study entry or within 6 months from rst transplant. Delaying the second high-dose therapy cycle beyond this time limit probably permits signicant tumor growth so that net tumor cytoreduction beyond the residual tumor burden postrst transplant could not be effected. The greater importance of dose-dense therapy rather than attaining CR status (which was signicant on univariate analysis) may reect the heterogeneity in residual tumor burden among CR patients. Collectively, these data support the importance of high-dose therapy for overcoming resistance mechanisms with which myeloma cells are abundantly endowed, even before any therapeutic intervention, explaining the low incidence of true CR in the 5% range with standard therapy and the lack of cure with traditional treatment.1 A comparison of Total Therapy with
Table 6. Multivariate Analysis of Pretreatment and Postintervention Variables (N 229)
EFS RR

other high-dose regimens is difficult because of heterogeneity of induction and high-dose regimens as well as response requirements before transplant. Cunningham reported on 53 chemotherapy-responsive patients receiving MEL 200 mg/m2 and ABMT, who experienced 2% TRM, CR of 75%, and median EFS/OS durations of 2.0/6.7 years.8 An update by Powles et al11 of 195 consecutive newly diagnosed patients under age 70 receiving modied VAD induction and mainly MEL 200 mg/m2based autotransplants (72% of initial patients) reported a CR rate of 53% and EFS/OS durations of 2.0/4.5 years. Using conditioning with combination chemotherapy comprising MEL, carmustine (BCNU), HDCTX, etoposide, and TBI 1,200 cGy to 63 mainly untreated patients with a median age of 44 years, Fermand et al12 observed TRM of 11%, CR of 20%, and EFS/OS durations of 3.6/6.4 years. Harousseau et al,13 treating 133 newly diagnosed patients with MEL 140 mg/m2 TBI 850 cGy noted 4% TRM, 37% CR, and EFS/OS of 2.0/3.8 years. A recent update of the IFM-90 trial33 comparing standard chemotherapy with a
Table 7. Grade III/IV Nonhematologic Toxicity
Tx-2 Toxicity* VAD HDCTX EDAP Tx-1 No TBI (TBI) (N 224) (N 218) (N 203) (N 195) (N 131) (N 20)

None Nausea/ vomiting Mucositis Diarrhea Bacteremia/ pneumonia Thromboembolic events Cap leak syndrome Early death

68

36

75

33

35

10

2 2 1 17

10 1 5 28

3 1 1 11

26 39 13 25

24 29 11 31

35 35 10 40

OS

RR

No 11/13q .481 .0004 2M 4.0 mg/L .534 .0006 Any second Tx .307 .001 Time to second Tx 1.005 .03 Any first CR NA* .17 Time to first CR NA* .42

No 11/13q .386 .0001 Any second Tx .200 .0002 Time to second Tx 1.008 .0005 Time to first CR 1.001 .02 2M 4.0 mg/L .609 .03 Any first Tx NA* .06

10 0 2

11 10 1

2 0 1

2 0 1

0 1 2

0 0 5

*RR estimates are not calculated for variables excluded from the final model. Abbreviation: RR, relative risk.

*Percent of N by phase of therapy. Excludes 11 allotransplants and 3 MUD transplants.

From bloodjournal.hematologylibrary.org at MARQUETTE UNIV on October 2, 2011. For personal use only.

TOTAL THERAPY FOR NEWLY DIAGNOSED MM

63

single autotransplant (MEL 140 mg/m2 TBI 800 cGy) in 200 untreated patients under age 65 showed median EFS/OS durations of 2.3/4.8 years after transplant compared with 4.2/ 6.8 years among the 140 patients under age 65 without any prior therapy enrolled in Total Therapy. In light of the above data, Total Therapy clearly effects an outstanding clinical outcome at acceptable morbidity and a low treatment (not just transplant)related mortality of 7% at 2 years. Despite its complexity, all phases of Total Therapy could be applied in a timely fashion, so that 95% of patients will have completed induction by 6 months, rst transplant (performed in 84% of all patients) by 8 months, and second transplant (performed in 71% of all patients) by 15 months. Obvious questions concern the need for multiple induction regimens before transplant and for two cycles of high-dose therapy. The latter is currently being addressed by the IFM-94 trial randomizing patients to one versus two transplants using MEL 140 mg/m2 TBI 800 cGy as the myeloablative regimen in both arms, preceded by MEL 140 mg/m2 in the tandem transplant group.34 A preliminary analysis of the rst 200 patients with a median follow-up of 2 years from diagnosis failed to show a difference in CR rate or EFS and OS. The lack of difference in CR rate is difficult to explain, although divergent results of the IFM-90 trial comparing standard with high-dose therapy emerged only beyond 2 years. When documented, most pretransplant induction regimens yield CR rates of no more than 5% after 4 cycles of either VAD or VMCP (vincristine, melphalan, cyclophosphamide, prednisone)/VBAP (vincristine, carmustine, doxorubicin, prednisone) that do not seem to increase when such therapy is continued as typically practiced in standard therapy trials.33 However, with Total Therapy, the incidence of at least PR ( 75% tumor cytoreduction and normal bone marrow morphology) had increased from 34% to 65% whereas the CR rate had risen from 5% to 15%. Whether the nal PR CR rate of 83% and the CR rate of 41% at the completion of Total Therapy (intent-to-treat) would also have been accomplished with minimal induction such as dexamethasone pulsing or VAD is difficult to determine except in the context of a randomized trial. However, in as much as CR status is a sine qua non for long-term disease control, ideally, each cycle of therapy should be maximally cytoreductive and contribute to raising the CR rate as accomplished in Total Therapy. Unfortunately, compared with acute myeologenous leukemia where CR is obtained in the majority of patients within one cycle of cytarabine-anthracycline combination, the median time to CR even with complex induction and tandem transplant exceeded 8 months. From the available literature, it is clear that high CR rates (50% range) require myeloablative therapy either with a single course using more hazardous chemoradiotherapy12 or repeated applications of high-dose therapy as practiced with Total Therapy. The latter approach seems to be better tolerated and applicable to patients up to age 70 and, more importantly, permits adjustments in dosing and timing depending on tolerance of and responsiveness to the rst cycle. Based on the lack of deleterious effects of advanced age35 and renal insufficiency,36 we recommend that autotransplants should be considered for all patients with symptomatic my-

eloma, which requires strict avoidance of potentially stem celltoxic standard therapy before PBSC collection. Based on analysis of tandem transplant trials in 551 patients with prior therapy of variable durations that identied three dominant risk factors for EFS, namely cytogenetics, 2M, and duration of therapy before rst transplant,37 our current approach uses a risk-based algorithm matching disease risk with the anticipated risk of therapeutic intervention. Tandem autotransplants with MEL 200 mg/m2 represent the standard backbone of therapy. Posttransplant, idiotype, or dendritic cell vaccination is evaluated in good-risk patients (all three favorable variables present)38-41 and combination chemotherapy with dexamethasone, cyclophosphamide, etoposide, and cisplatin42 in those with high risk. In this fashion, we hope to decrease the risk of relapse and increase the fraction of patients enjoying sustained CR, now obtained in one half of patients entering CR ( 5 years). Longer follow-up will be required to determine the fraction of patients that can be considered cured with Total Therapy, because approximately 20% of patients achieving CR have not relapsed at 10 years even after a single mainly TBI-based autotransplant.43 Future clinical trial questions in myeloma should build on the Total Therapy experience. Until more specic myeloma therapy has been developed in phase I and II trials for advanced and refractory disease, front line regimens should consider a Total Therapylike approach with cure as an objective of treatment which hence needs to aim at increasing CR rates beyond the current level of 40% to 50%. Thus, ne-tuning strategies are not yet warranted. Rather, standard dose consolidation chemotherapy versus additional cycles of PBSC-supported high-dose therapy after an MEL-based tandem transplant deserves exploration.
NOTE ADDED IN PROOF

Further analysis of data indicated that the adverse implications of chromosome 11 and 13 abnormalities (49 patients) are entirely due to partial or complete deletions of chromosome 13,44 present in 41 patients (18%).
ACKNOWLEDGMENT We acknowledge the support provided by the Bone Marrow Transplant Team of the University of Arkansas for Medical Sciences and the Arkansas Cancer Research Center. We particularly thank the many referring physicians who entrusted us with their patients care, the Myeloma Data Management Team for their tireless effort, and Caran Hammonds for excellent assistance in manuscript preparation. REFERENCES 1. Alexanian R, Dimopoulos M: The treatment of multiple myeloma. N Engl J Med 7:484, 1994 2. Barlogie B: Plasma cell myeloma, in E. Beutler, M. Lichtman, B. Coller, T. Kipps (eds): Hematology. Williams Hematology, Fifth Edition. New York, NY, McGraw-Hill, 1995, p 1109 3. McElwain T, Powles R: High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet 2:822, 1983 4. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R: High dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67:1298, 1986 5. Barlogie B, Alexanian R, Dicke K, Zagars G, Spitzer G, Jagannath S, Horwitz L: High dose chemoradiotherapy and autologous bone

From bloodjournal.hematologylibrary.org at MARQUETTE UNIV on October 2, 2011. For personal use only.

64

BARLOGIE ET AL

marrow transplantation for resistant multiple myeloma. Blood 70:869, 1987 6. Selby PJ, McElwain TJ, Nandi AC, Perren TJ, Powles RL, Tillyet CR, Osbourne RJ, Slevin ML, Malpas JS: Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 66:55, 1987 7. Gore ME, Selby PJ, Virer C, Clark P, Melbrum M, Millar B, Bell J, Maitland J, Milan S, Jusdon I, Zuiable A, McElwain T: Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 2:879, 1989 8. Cunningham D, Paz-Ares L, Milan S, Powles R, Nicholson M, Hickish T, Selby P, Treveavan J, Viner C, Malpas J, Slevin M, Findlay M, Raymond J, Gore ME: High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 12:759, 1994 9. Bjorkstrand B, Ljungman P, Bird JM, Samson D, Gahrton G: Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant 15:367, 1995 10. Bensinger W, Rowley S, Demirer T, Lilleby K, Schiffman K, Clift RA, Appelbaum FR, Barnett T, Storb R, Chancey T, Maziarz RT, Klarnet J, MacSweeney P, Holmberg L, Maloney DG, Weaver CH, Buckner CD: High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 14:1447, 1996 11. Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J, Singhal S, Kulkarni S, Viner C, Gore M, Cunningham D, Treleaven J: Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 20:435, 1997 12. Fermand JP, Levy Y, Gerota, Benbunan M, Cosset JM, Castaigne S, Seligmann M, Brouet JC: Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 73:20, 1989 13. Harousseau J, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, Bourhis JH, Caillot D, Boasson M, Abgrall JF: Autologous stem cell transplantation after rst remission induction treatment in multiple myeloma: A report of the French registry on autologous transplantation in multiple myeloma. Blood 85:3077, 1995 14. Vesole D, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, Crowley J: High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 84:950, 1994 15. Attal M, Harousseau J, Stoppa A, Sotto J, Fuzibet J, Rossi J, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91, 1996 16. Jagannath S, Tricot G, Vesole D, Desikan KR, Munshi N, Siegel D, Crowley J, Bracy D, Mattox S, Naucke S, Barlogie B: Total Therapy (TT) with tandem autotransplants (2TX) for 231 newly diagnosed patients (PTS) with multiple myeloma (MM). Blood 888:685a, 1996 (abstr) 17. Barlogie B, Jagannath S, Vesole D, Tricot G, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789, 1997 18. Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353, 1984 19. Gianni A, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, Bonadonna G: Granulocyte-macrophage colony-stimulating factor to harvest circulating hematopoietic stem cells for autotransplantation. Lancet 2:580, 1989 20. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L,

Cheson B, Crowley J, Barlogie B: Peripheral blood stem cell transplant for multiple myeloma: Identication of favorable variables for rapid engraftment in 225 patients. Blood 85:588, 1995 21. Barlogie B, Alexanian R, Cabanillas F: Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma. J Clin Oncol 7:1514, 1989 22. Greipp P, Raymond N, Kyle R, OFallon W: Multiple myeloma: Signicance of plasmablastic subtype in morphological classication. Blood 65:305, 1985 23. Durie BGM, Salmon S: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842, 1975 24. Sawyer J, Waldron J, Jagannath S, Barlogie B: Cytogenetics ndings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82:41, 1995 25. Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W: Histologic classication and staging of multiple myeloma. Am J Clin Pathol 87:342, 1987 26. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958 27. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Reports 50:163, 1966 28. Anderson JR, Cain KC, Gebler RD: Analysis of survival by tumor response. J Clin Oncol 1:710, 1983 29. Cox DR: Regression models and life-tables (with discussion). J Royal Stat Soc, Series B, 34:187, 1972 30. Kalbeisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980, p 168 31. Tricot G, Sawyer J, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer JR: Poor prognosis in multiple myeloma is associated only with partial or complete deletion of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250, 1995. 32. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A: C-reactive protein and beta-2-microglobulin produce a simple and powerful myeloma staging system. Blood 80:733, 1992 33. Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R for the Intergroupe Francais Du Myelome; CHU Purpan, Toulouse, France: High dose therapy in multiple myeloma: An updated analysis of the IFM 90 protocol. Blood 90:418a, 1997 (abstr) 34. Attal M, Payen C, Facon T, Michaux JL, Guilhot F, Moconduit M, Fuzibet JG, Caillot D, Dorvaux V, Harousseau JL, Cahn JY, Grobois B, Stoppa AM, Ifrah N, Sotto JJ, Pignon B, Bataille R for the IFM; Service dHematologie, Hospital Purpan, Toulouse, France: Single versus double transplant in myeloma: A randomized trial of the InterGroupe Francais du Myelome (IFM). Blood 90:418a, 1997 (abstr) 35. Siegel D, Jagannath S, Desikan KR, Tricot G, Vesole D, Fassas A, Singhal S, Mehta J, Hood S, Barlogie B: Similar prognosis after tandem autotransplants (TAT) for myeloma 65 yr and 65 yr. Blood 90:419a, 1997 (abstr) 36. Tricot G, Alberts DS, Johnson CS, Roe DJ, Dorr RT, Vesole DH, Jagannath S, Meyers R, Barlogie B: Safety of autotransplants with high dose melphalan in renal failure: A pharmacokinetic and toxicity study. Clin Cancer Res 6:947, 1996 37. Barlogie B: Advances in therapy of multiple myeloma: Lessons from acute leukemia. Clin Cancer Res 3:2605, 1997 38. Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL: Transfer of myeloma idiotype-specic immunity form an actively immunized marrow donor. Lancet 345:1016, 1995 39. Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S,

From bloodjournal.hematologylibrary.org at MARQUETTE UNIV on October 2, 2011. For personal use only.

TOTAL THERAPY FOR NEWLY DIAGNOSED MM

65

Jeddi-Tehrani M, Ruden U, Lefvert A, Holm G, Mellstedt H: Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specic T-cell responses. Blood 91:2459, 1998 40. Wen Y, Ling M, Bailey-Wood R, Lim S: Idiotype protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 4:957, 1998 41. Reichardt V, Okada C, Benike C, Long G, Engelman E, Blume K, Levy R: Idiotype vaccination using dendritic cells for multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. Blood 88:481a, 1996 (abstr)

42. Munshi N, Desikan KR, Jagannth S, Siegel D, Bracy D, Tricot G, Barlogie B: Dexamethasone, cyclophosphamide, etoposide and cisplatinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation (AT). Blood 88:586a, 1996 (abstr) 43. Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Alexanian R, Crowley J, Tricot G: Long term follow-up after high dose therapy for high risk multiple myeloma. Bone Marrow Transplant 21:1101, 1998 44. Barlogie B, Sawyer J, Ayers D, Desikan R, Siegel D, Singhal S, Mehta J, Munshi N, Anaissie E, Drach J, Shaughnessy J: Chromosome 13 myeloma ( 13 MM) is a distinct entity with poor prognosis despite tandem autotransplants. Blood 92:258a, 1998 (abstr; suppl 1)